Ye MS - Genscript Biotech Pres CoFounder

All Insiders . USA . 
Stock . Genscript Biotech . Stakeholders . Insider . Ye MS
GNNSF Stock  USD 1.37  0.01  0.72%   

Insider

Ye MS is Pres CoFounder of Genscript Biotech
Age 55
Phone86 25 5889 7288
Webhttps://www.genscript.com

Genscript Biotech Management Efficiency

The company has return on total asset (ROA) of (0.1165) % which means that it has lost $0.1165 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5574) %, meaning that it generated substantial loss on money invested by shareholders. Genscript Biotech's management efficiency ratios could be used to measure how well Genscript Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
Genscript Biotech has accumulated 121.07 M in total debt with debt to equity ratio (D/E) of 0.56, which is about average as compared to similar companies. Genscript Biotech has a current ratio of 2.86, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genscript Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, Genscript Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genscript Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genscript to invest in growth at high rates of return. When we think about Genscript Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Alexander BakkerMerus BV
58
Lena MoranAdamsTelix Pharmaceuticals Limited
N/A
William AnnettLineage Cell Therapeutics
70
Jordan HermanOxford Nanopore Technologies
N/A
David MDNuvation Bio
54
John SchoellermanOxford Nanopore Technologies
N/A
Michelle DoigNuvation Bio
46
DSc FACPOvid Therapeutics
65
Jyoti BappScTelix Pharmaceuticals Limited
N/A
Jeff KnightCrinetics Pharmaceuticals
53
Keith MBAKeros Therapeutics
54
Richard ComptonOxford Nanopore Technologies
N/A
BBus FCPATelix Pharmaceuticals Limited
57
Marni KottleKronos Bio
N/A
Carrie MDZentalis Pharmaceuticals Llc
54
Stacy MarkelNuvation Bio
59
Tim CowperOxford Nanopore Technologies
N/A
Kevin CappsCrinetics Pharmaceuticals
N/A
Andreas MDTelix Pharmaceuticals Limited
N/A
Sarah LapworthOxford Nanopore Technologies
N/A
Richard MDLyell Immunopharma
72
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, the Peoples Republic of China, Japan, the other Asia Pacific regions, and internationally. Genscript Biotech Corporation was founded in 2002 and is headquartered in Nanjing, the Peoples Republic of China. Genscript Biotech operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5573 people. Genscript Biotech [GNNSF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-0.56
Return On Asset-0.12

Genscript Biotech Leadership Team

Elected by the shareholders, the Genscript Biotech's board of directors comprises two types of representatives: Genscript Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genscript. The board's role is to monitor Genscript Biotech's management team and ensure that shareholders' interests are well served. Genscript Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genscript Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Shiniu Wei, Chief Officer
Li Zhu, Vice President - Strategy
Brian Min, CEO Bus
Zhenyu Liu, Chief Officer
Jiange Meng, Vice President - Finance, Executive Director
Weihui Shao, Chief Officer
Chifa Zhang, Department head - industry synthetic biology product segment
ACIS ACS, Company Sec
Ye MS, Pres CoFounder
ChuanChu Chou, Department head - Preclinical Drug Development Service Business Segment

Genscript Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Genscript Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.56
Return On Asset-0.12
Profit Margin(0.66) %
Operating Margin(0.64) %
Current Valuation5.11 B
Shares Outstanding2.12 B
Shares Owned By Insiders38.31 %
Shares Owned By Institutions24.68 %
Price To Earning200.00 X
Price To Book6.65 X

Currently Active Assets on Macroaxis

RSIRush Street Interactive
OKTAOkta Inc
BACBank of America
SSentinelOne
WDWalker Dunlop

Other Information on Investing in Genscript Pink Sheet

Genscript Biotech financial ratios help investors to determine whether Genscript Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genscript with respect to the benefits of owning Genscript Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY